We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction (NASA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01245075
Recruitment Status : Unknown
Verified December 2016 by Jens Kuhn, University of Cologne.
Recruitment status was:  Recruiting
First Posted : November 22, 2010
Last Update Posted : December 7, 2016
Information provided by (Responsible Party):
Jens Kuhn, University of Cologne

Brief Summary:

The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the Nucleus accumbens (NAc) as a novel treatment in severe opioid addiction. The included patients have been treated so far with a substitute in form of methadone.

Our hypothesis is that bilateral DBS of the NAc will significantly reduce the craving for heroin and thus enable the patients to decrease their Levomethadone-dosage substantially.

Condition or disease Intervention/treatment Phase
Addiction Other: Deep brain stimulation Other: Placebo Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction
Study Start Date : January 2011
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Deep Brain Stimulation
Stimulator setting is ON
Other: Deep brain stimulation
Deep brain stimulation on

Sham Comparator: Placebo
Stimulator setting is OFF
Other: Placebo
deep brain stimulation off

Primary Outcome Measures :
  1. Reduction of Levomethadone [ Time Frame: seven month ]
    Reduction of the dosage of the substitute (in detail Levomethadone) comparing baseline and the particular ward rounds during and at the end of the crossover-design.

Secondary Outcome Measures :
  1. Drug seeking, goal directed behavior, Craving, Psychological components Laboratory parameters in the urine (parallel consumption of other drugs) [ Time Frame: seven month ]
    Drug seeking and goal directed behavior (accessed with EEG) Craving (10-point visual analog scale (VAS)) Psychological components (Anxiety (HAMA); Depression (BDI-II); Quality of life (MSLQ) . Laboratory parameters in the urine (parallel consumption of other drugs)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years
  • Proficiency in the German language
  • Long lasting heroin addiction (fulfilled diagnostic-criteria according to DSM-IV,ICD-10)
  • At least one detoxication-treatment without a long-term period of abstinence has already taken place
  • Long-term inpatient treatment to support abstinence have occurred
  • Free patient's decision / Informed Consent (existing comprehensive ability in meaning, methodology and execution of the study and ability of acceptance)
  • If prior medication, stable dosage of psychopharmacological drugs over the last three months, which shall, after checking be retained during the study
  • Substitution treatment with constant dose within the last three months before study inclusion

Exclusion Criteria:

  • Hospitalization by PsychKG
  • Clinical relevant psychiatric comorbidity (schizophrenic psychoses, bipolar affective diseases, severe personality disorder)
  • Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/ heart defibrillator
  • Current and in the last six months existent paranoid-hallucinated symptomatology
  • Foreign aggressiveness in the last six months
  • Verbal IQ < 85 (evaluated with the German Mehrfachauswahl-Intelligenz-Test (MWT-A/B))
  • Stereotactic respectively neurosurgical intervention in the past
  • Neoplastical neurological diseases
  • Contraindications of a stereotactic operation, e.g. increased bleeding-disposition, cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular diseases)
  • Serious and instable organic diseases (e.g. instable coronal heart disease)
  • tested positively for HIV
  • pregnancy and/or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01245075

Layout table for location contacts
Contact: Jens Kuhn, MD ++49221-478-4005 jens.kuhn@uk-koeln.de
Contact: Veerle Visser-Vandewalle, MD ++49221-478-82792 veerle.visser-vandewalle@uk-koeln.de

Layout table for location information
University of Cologne Recruiting
Cologne, Germany, 50924
Sponsors and Collaborators
Jens Kuhn
Layout table for investigator information
Principal Investigator: Veerle Visser-Vandewalle, MD University of Cologne
Principal Investigator: Jens Kuhn, MD University of Cologne
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jens Kuhn, Prof. Dr., University of Cologne
ClinicalTrials.gov Identifier: NCT01245075    
Other Study ID Numbers: 10-090
First Posted: November 22, 2010    Key Record Dates
Last Update Posted: December 7, 2016
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior
Narcotic-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders